BR0013252A - Micofenolato mofetila em associação com peg-ifn-alfa - Google Patents
Micofenolato mofetila em associação com peg-ifn-alfaInfo
- Publication number
- BR0013252A BR0013252A BR0013252-7A BR0013252A BR0013252A BR 0013252 A BR0013252 A BR 0013252A BR 0013252 A BR0013252 A BR 0013252A BR 0013252 A BR0013252 A BR 0013252A
- Authority
- BR
- Brazil
- Prior art keywords
- ifn
- peg
- alfa
- combination
- mycophenolate mofetil
- Prior art date
Links
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 title 1
- 229960004866 mycophenolate mofetil Drugs 0.000 title 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 abstract 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 229940014456 mycophenolate Drugs 0.000 abstract 1
- 229960000951 mycophenolic acid Drugs 0.000 abstract 1
- 210000005259 peripheral blood Anatomy 0.000 abstract 1
- 239000011886 peripheral blood Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99115950 | 1999-08-13 | ||
| US18790700P | 2000-03-08 | 2000-03-08 | |
| PCT/EP2000/007666 WO2001012214A2 (fr) | 1999-08-13 | 2000-08-08 | Mofetilmycophenolate associe a peg-ifn-alpha |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0013252A true BR0013252A (pt) | 2002-04-16 |
Family
ID=29762814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0013252-7A BR0013252A (pt) | 1999-08-13 | 2000-08-08 | Micofenolato mofetila em associação com peg-ifn-alfa |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1220683A2 (fr) |
| JP (1) | JP2003507339A (fr) |
| CN (1) | CN1368887A (fr) |
| AU (1) | AU7408200A (fr) |
| BR (1) | BR0013252A (fr) |
| CA (1) | CA2380653A1 (fr) |
| HU (1) | HUP0202525A3 (fr) |
| MX (1) | MXPA02001296A (fr) |
| PE (1) | PE20010490A1 (fr) |
| PL (1) | PL357367A1 (fr) |
| RU (1) | RU2002105485A (fr) |
| TR (1) | TR200200401T2 (fr) |
| WO (1) | WO2001012214A2 (fr) |
| ZA (1) | ZA200200280B (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0307553D0 (en) * | 2003-04-01 | 2003-05-07 | Novartis Ag | Organic compounds |
| DE602005013922D1 (de) | 2004-02-24 | 2009-05-28 | Japan Tobacco Inc | Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor |
| US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| KR20070045244A (ko) * | 2004-08-12 | 2007-05-02 | 쉐링 코포레이션 | 안정한 페길화된 인터페론 제형 |
| US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
| US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
| WO2010110503A1 (fr) * | 2009-03-27 | 2010-09-30 | 주식회사 중외제약 | Protéine fusionnée d'interféron-α (ifn-α) comprenant l'ifn-α et un peptide de transduction cytoplasmique (ctp) |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| CH707029B1 (de) | 2011-10-21 | 2015-03-13 | Abbvie Inc | Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon. |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| EP2583680A3 (fr) | 2011-10-21 | 2013-06-12 | Abbvie Inc. | Traitement seul (PSI-7977) ou combinatoire dans l'utilisation pour le traitement du VHC |
| EP3215193B1 (fr) * | 2014-11-06 | 2023-10-04 | PharmaEssentia Corporation | Régime posologique pour l'interféron pégylé |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| MY125300A (en) * | 1999-02-26 | 2006-07-31 | Inst Of Molecular And Cell Biology | Synergistic combination for treatment of viral-mediated diseases |
-
2000
- 2000-08-08 PE PE2000000804A patent/PE20010490A1/es not_active Application Discontinuation
- 2000-08-08 RU RU2002105485/15A patent/RU2002105485A/ru not_active Application Discontinuation
- 2000-08-08 CN CN00811397A patent/CN1368887A/zh active Pending
- 2000-08-08 EP EP00962297A patent/EP1220683A2/fr not_active Withdrawn
- 2000-08-08 CA CA002380653A patent/CA2380653A1/fr not_active Abandoned
- 2000-08-08 WO PCT/EP2000/007666 patent/WO2001012214A2/fr not_active Application Discontinuation
- 2000-08-08 PL PL00357367A patent/PL357367A1/xx not_active Application Discontinuation
- 2000-08-08 MX MXPA02001296A patent/MXPA02001296A/es unknown
- 2000-08-08 AU AU74082/00A patent/AU7408200A/en not_active Abandoned
- 2000-08-08 HU HU0202525A patent/HUP0202525A3/hu unknown
- 2000-08-08 BR BR0013252-7A patent/BR0013252A/pt not_active IP Right Cessation
- 2000-08-08 TR TR2002/00401T patent/TR200200401T2/xx unknown
- 2000-08-08 JP JP2001516559A patent/JP2003507339A/ja active Pending
-
2002
- 2002-01-11 ZA ZA200200280A patent/ZA200200280B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001012214A2 (fr) | 2001-02-22 |
| JP2003507339A (ja) | 2003-02-25 |
| ZA200200280B (en) | 2003-04-11 |
| HUP0202525A2 (hu) | 2002-11-28 |
| CA2380653A1 (fr) | 2001-02-22 |
| CN1368887A (zh) | 2002-09-11 |
| WO2001012214A3 (fr) | 2001-10-04 |
| AU7408200A (en) | 2001-03-13 |
| PE20010490A1 (es) | 2001-04-27 |
| TR200200401T2 (tr) | 2002-06-21 |
| HUP0202525A3 (en) | 2003-11-28 |
| MXPA02001296A (es) | 2002-07-22 |
| EP1220683A2 (fr) | 2002-07-10 |
| RU2002105485A (ru) | 2004-01-27 |
| PL357367A1 (en) | 2004-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0013252A (pt) | Micofenolato mofetila em associação com peg-ifn-alfa | |
| BR0014525A (pt) | Processo de tratamento de distúrbios metabólicos, especialmente diabetes, ou uma doença ou condição associada com diabetes | |
| RU2003119460A (ru) | Применение пэг-интерферона-а(пэг-inf-а) и рибавирина для лечения хронического гепатита с | |
| BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
| CY1111088T1 (el) | Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση | |
| BRPI0108977B8 (pt) | compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
| BR9206398A (pt) | Peptídio, processo para promover a liberação de níveis de hormônio de crescimento em um animal, composição farmacêutica, processos para promover a liberação e elevação de níveis de hormônio de crescimento no sangue, para tratar nanismo pituitário hipotalâmico, osteoporose ou queimaduras, para promover a cicatrização de feridas, a recuperação de cirurgias ou recuperação de doenças debilitantes agudas/crônicas, para prevenir ou reduzir caquexia em pacientes com câncer, para promover o anabolismo e/ou evitar catabolismo em seres humanos, para aumentar o músculo em um animal e/ou diminuir a gordura do corpo, para melhorar o padrão de lipídios no soro em seres humanos, e para preparar compostos | |
| BR9408378A (pt) | Composto sal farmaceuticamente aceitável composição farmacêutica e processos para o tratamento de um paciente que sofreu um derrame e que sofre de uma condição de perda progressiva de função de sistema nervoso central e para melhorar os efeitos colaterais causados em um paciente por tratamento antineoplástico de doença que produz danos oxidativos | |
| ATE219363T1 (de) | Lösliche prodrugs von paclitaxel | |
| HUP9802339A2 (hu) | Darifenacint tartalmazó gyógyászati készítmények | |
| BR0010498A (pt) | Composições modernas de medicamentos à base de compostos anticolinergicamente ativos e beta-miméticos | |
| BR0008039A (pt) | Combinações de formoterol e um sal de tiotrópio | |
| BR0316685A (pt) | Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade | |
| BR0315283A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de doenças neurológicas ou de doenças inflamatórias do trato respiratório superior | |
| BR0015974A (pt) | Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto | |
| BR0212078A (pt) | Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto | |
| BRPI0411451A (pt) | formas de dosagens orais de memantina | |
| BR0014946A (pt) | Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina | |
| KR950007848A (ko) | (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법 | |
| KR970025615A (ko) | 암 전이 억제제 | |
| EP1431286A3 (fr) | Derives du prodigiosine destines au traitement du cancer et des maladies virales | |
| JP2002544227A5 (fr) | ||
| JP2003514025A5 (fr) | ||
| AR025549A1 (es) | Mofetil micofelonato en asociacion con peg-ifn-alfa | |
| KR960028907A (ko) | 암환자를 치료하기 위한 세트랄린의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1927 DE 11/12/2007. |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 38/21 (2006.01), A61K 31/365 (2006.01), A61P |